Treatment of HIV: Agents 1999 and beyond protease inhibitors and other agents
Ramírez-Ronda, C.H.; Ramírez-Ramírez, C.R.
Boletin de la Asociacion Medica de Puerto Rico 91(1-6): 60-63
1999
ISSN/ISBN: 0004-4849 Document Number: 703022
HIV-1 protease inhibitors were first introduced into clinical trials more than five years ago (1,2). These drugs bind competitively to the cleavage site within the HIV-1 aspartyl protease enzyme. The enzyme is a C2 symmetric molecule that cleaves specific regions of the gag precursor molecule of HIV1 into functional domains. When this enzymes action is blocked, it interrupts the normal processing of viral proteins, resulting in production of noninfectious virions from an infected cell. The HIV-1 protease inhibitors represent the most potent class of currently available agents. Four protease inhibitors are currently available and at least six other agents are under development.
Document emailed within 1 workday
